Clopidogrel Inhibits CYP2C19-Dependent Hydroxylation of Omeprazole Related to CYP2C19 Genetic Polymorphisms

This study explores the impact of clopidogrel on the pharmacokinetics of omeprazole related to CYP2C19 genetic polymorphisms. Twelve healthy volunteers (6 CYP2C19*1/*1, 5 CYP2C19*2/*2, and 1 CYP2C19*2/*3) are enrolled in a 2‐phase randomized crossover trial. In each phase, the volunteers are adminis...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical pharmacology 2009-05, Vol.49 (5), p.574-581
Hauptverfasser:	Chen, B. L., Chen, Y., Tu, J. H., Li, Y. L., Zhang, W., Li, Q., Fan, L., Tan, Z. R., Hu, D. L., Wang, D., Wang, L. S., OuYang, D. S., Zhou, H. H.
Format:	Artikel
Sprache:	eng
Schlagworte:	2-Pyridinylmethylsulfinylbenzimidazoles - blood Anti-Ulcer Agents - blood Anti-Ulcer Agents - pharmacokinetics Area Under Curve Aryl Hydrocarbon Hydroxylases - genetics Aryl Hydrocarbon Hydroxylases - metabolism Chromatography, High Pressure Liquid Clopidogrel Cross-Over Studies CYP2C19 Cytochrome P-450 CYP2C19 Drug Interactions Drug Therapy, Combination genetic polymorphism Genotype Humans Hydroxylation inhibition Male omeprazole Omeprazole - blood Omeprazole - pharmacokinetics Platelet Aggregation Inhibitors - administration & dosage Platelet Aggregation Inhibitors - pharmacology Polymorphism, Genetic Spectrophotometry, Ultraviolet Sulfoxides - metabolism Ticlopidine - administration & dosage Ticlopidine - analogs & derivatives Ticlopidine - pharmacology Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!